KR102599401B1 - 엔벨로프 바이러스의 비-유전적 변형 - Google Patents

엔벨로프 바이러스의 비-유전적 변형 Download PDF

Info

Publication number
KR102599401B1
KR102599401B1 KR1020197012062A KR20197012062A KR102599401B1 KR 102599401 B1 KR102599401 B1 KR 102599401B1 KR 1020197012062 A KR1020197012062 A KR 1020197012062A KR 20197012062 A KR20197012062 A KR 20197012062A KR 102599401 B1 KR102599401 B1 KR 102599401B1
Authority
KR
South Korea
Prior art keywords
tumor
seq
virus
peptide
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197012062A
Other languages
English (en)
Korean (ko)
Other versions
KR20190053260A (ko
Inventor
빈센조 셀룰로
크리스티안 카파소
에르코 일로스마키
Original Assignee
발로 테라퓨틱스 오와이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 발로 테라퓨틱스 오와이 filed Critical 발로 테라퓨틱스 오와이
Publication of KR20190053260A publication Critical patent/KR20190053260A/ko
Application granted granted Critical
Publication of KR102599401B1 publication Critical patent/KR102599401B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020197012062A 2016-09-27 2017-09-06 엔벨로프 바이러스의 비-유전적 변형 Active KR102599401B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1616365.1A GB201616365D0 (en) 2016-09-27 2016-09-27 Non-genetic modification of enveloped viruses
GB1616365.1 2016-09-27
PCT/EP2017/072366 WO2018059896A1 (en) 2016-09-27 2017-09-06 Non-genetic modification of enveloped viruses

Publications (2)

Publication Number Publication Date
KR20190053260A KR20190053260A (ko) 2019-05-17
KR102599401B1 true KR102599401B1 (ko) 2023-11-06

Family

ID=57539741

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197012062A Active KR102599401B1 (ko) 2016-09-27 2017-09-06 엔벨로프 바이러스의 비-유전적 변형

Country Status (12)

Country Link
US (1) US10982194B2 (enExample)
EP (1) EP3519565A1 (enExample)
JP (2) JP7258746B2 (enExample)
KR (1) KR102599401B1 (enExample)
CN (1) CN109890957A (enExample)
AU (2) AU2017337753B2 (enExample)
BR (1) BR112019005825A2 (enExample)
CA (1) CA3035104A1 (enExample)
GB (1) GB201616365D0 (enExample)
RU (1) RU2760521C2 (enExample)
WO (1) WO2018059896A1 (enExample)
ZA (1) ZA201902388B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907413D0 (en) * 2019-05-24 2019-07-10 Univ Helsinki Viral vector
WO2020252039A1 (en) * 2019-06-12 2020-12-17 Biontech Us Inc. Neoantigen compositions and uses thereof
US20220305099A1 (en) * 2019-08-27 2022-09-29 Turnstone Biologics Corp. Methods for inducing an immune response against neoantigens
GB202013834D0 (en) * 2020-09-03 2020-10-21 Valo Therapeutics Oy PeptiVAX therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1257286C (zh) 1998-08-27 2006-05-24 森泰莱昂公司 用于递送异源基因的定向腺病毒载体
MXPA01005389A (es) * 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
IL145899A0 (en) * 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
CN100352921C (zh) 1999-05-06 2007-12-05 威克福雷大学 用于鉴定引起免疫反应的抗原的组合物和方法
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
WO2004000220A2 (en) 2002-06-21 2003-12-31 Genetix Pharmaceuticals, Inc. Methods for purifying viral particles for gene therapy
US20070243170A1 (en) * 2002-10-07 2007-10-18 The University Of Chicago Targeting of Herpes Simplex Virus to Specific Receptors
AU2004224761A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
HRP20120845T1 (hr) * 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
WO2005060541A2 (en) 2003-12-01 2005-07-07 Wisconsin Alumni Research Foundation Peptides and methods for inducing cellular resistance to infection
KR101157694B1 (ko) * 2003-12-17 2012-06-20 와이어쓰 엘엘씨 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
JP2008136381A (ja) * 2006-11-30 2008-06-19 Japan Health Science Foundation 改変型アデノウイルスベクター及びその作製方法
WO2009117656A2 (en) 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
NO2700405T3 (enExample) * 2008-05-29 2018-09-01
EP2349296B1 (en) * 2008-08-21 2017-04-05 Ottawa Hospital Research Institute Engineered synergistic oncolytic viral symbiosis
ES2335077B1 (es) 2008-12-30 2011-02-02 Instituto Aragones De Ciencias De La Salud Formulaciones para el recubrimiento y transporte de diversos elementos hacia los tumores.
US8609392B2 (en) * 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
US20130243731A1 (en) 2010-09-24 2013-09-19 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies
US20140140962A1 (en) 2011-04-29 2014-05-22 The Research Foundation Of State University Of New York Viruses modified with unnatural moieties and methods of use thereof
US20140349944A1 (en) * 2013-05-23 2014-11-27 Musc Foundation For Research Development Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases
RS65104B1 (sr) 2013-08-22 2024-02-29 Univ Pittsburgh Commonwealth Sys Higher Education Onkolitičke imunoterapije
BR112016009465A8 (pt) * 2013-10-28 2018-01-30 Univ Pittsburgh Commonwealth Sys Higher Education vetor de hsv oncolítico.
US10799568B2 (en) 2014-05-19 2020-10-13 Valo Therapeutics Oy Modified adenoviruses for cancer vaccines development

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOLOGY AND BIOENGINEERING. 2015, vol. 112, no. 6, pages 1102-1110.
JOURNAL OF LIPID RESEARCH. 2016.08.19., vol. 57, no. 10, pages 1778-1788.
ONCOIMMUNOLOGY. 2015, vol. 5, no. 4, page e110542.*

Also Published As

Publication number Publication date
NZ751251A (en) 2025-03-28
AU2017337753A1 (en) 2019-03-21
JP2019532631A (ja) 2019-11-14
JP2023029997A (ja) 2023-03-07
US10982194B2 (en) 2021-04-20
AU2023237201A1 (en) 2023-12-14
AU2017337753B2 (en) 2023-09-28
US20200010811A1 (en) 2020-01-09
RU2019110407A (ru) 2020-10-29
EP3519565A1 (en) 2019-08-07
RU2760521C2 (ru) 2021-11-26
BR112019005825A2 (pt) 2019-06-11
GB201616365D0 (en) 2016-11-09
JP7258746B2 (ja) 2023-04-17
ZA201902388B (en) 2020-10-28
WO2018059896A1 (en) 2018-04-05
AU2023237201B2 (en) 2025-06-05
CN109890957A (zh) 2019-06-14
CA3035104A1 (en) 2018-04-05
RU2019110407A3 (enExample) 2021-05-13
KR20190053260A (ko) 2019-05-17

Similar Documents

Publication Publication Date Title
AU2023237201B2 (en) Non-genetic modification of enveloped viruses
CN107050440B (zh) 疫苗组合物和其使用方法
KR100457647B1 (ko) 펩티드및애쥬번트에기초한면역조절용약제학적조성물
CN1738901B (zh) 用于调变免疫反应的模块化抗原转运蛋白分子(mat分子)和相关的构建体、方法和用途
CN114761438A (zh) 用于编程细胞外囊泡的重组多肽
Rueda et al. Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines
Abdel-Aal et al. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based toll-like receptor 2 ligand
AU2015364447B2 (en) Antigen delivery system
US20220088162A1 (en) Heterologous Prime Boost Vaccine
US20250236658A1 (en) Pdl2 compounds
CN111295200A (zh) 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒
CN114302740A (zh) 病毒载体
Skea et al. The immunotargeting approach to adjuvant-independent immunization with influenza haemagglutinin
US20240226279A1 (en) Human anti-coronavirus peptide vaccines and methods of their use
CN119156343A (zh) 搭载肽的载体系统及其用途
Ladjevardi et al. Erika AK Fletcher, Robert A. Cordfunke, 3, 13 Aikaterini Nasi, Gunilla Törnqvist, Rob RPM Valentijn, 5 Anna Bergqvist, 4 Marita Westhrin, 4 Wenche Rasch, 4 Frida Lindqvist, Inken Dillmann, Martin Lord, Neanke Bouwman, 5 Jacques J. Neefjes, 6 Kees LMC Franken, 7 Stephanie McArdle, 8 Murrium Ahmad, 8 Silvia Johansson, 9, 10 Ferry Ossendorp, 3 Michael Haggman, 10, 11 Maria Lampinen, Gustav Ullenhag, 9, 10
Fletcher et al. of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement
CN120789242A (zh) 一种egfr l858r突变特异性长肽疫苗及其应用
Schultz et al. peptide Assembly on the Membrane Determines the HIV-1 Inhibitory Activity of Dual-Targeting Fusion Inhibitor Peptides
NZ751506A (en) Immunotherapy for polyomaviruses

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190425

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200819

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211127

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220718

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211127

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220718

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220224

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221125

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20231017

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20230525

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20221018

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220718

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220224

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231102

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231102

End annual number: 3

Start annual number: 1

PG1601 Publication of registration